Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

NCT04231851 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT04231851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 19, 2020
Completion date
June 30, 2027
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia (aml) due to therapy, acute myeloid leukemia with myelodysplasia-related changes